| Description |
| Product Type |
Product Size |
| Tablets |
120'S |
| Product Company |
| Beacon Pharmaceuticals |
Abiraterone acetate 250mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmasol |
|
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Martin Dow |
Anastrozole 1mg |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Pertuzumab 420mg/14ml |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
| Content | Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer. | Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. So, it stops the growth of the cancer. | Anastrozole is a type of hormone treatment. It works by lowering the levels of oestrogen hormones in your body. It is mainly prescribed for women who have been through the menopause and have a type of cancer called hormone-dependent breast cancer. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. |
Reviews
There are no reviews yet.